Menquadfi Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The menquadfi market research report is one of a series of new reports that provides menquadfi market statistics, including menquadfi industry global market size, regional shares, competitors with a menquadfi market share, detailed menquadfi market segments, market trends and opportunities, and any further data you may need to thrive in the menquadfi industry. This menquadfi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing awareness about the disease, increasing prevalence of meningitis, increasing demand for meningococcal vaccines in developing countries, increase in global travel and increasing research and development activities pertaining to meningococcal vaccines. Major trends in the forecast period include the expansion of vaccination programs globally, development of new vaccine formulations, the expansion of vaccination coverage in emerging markets, growth in partnerships and collaborations among vaccine manufacturers and advancements in vaccine delivery technologies.

The increasing prevalence of meningitis is expected to drive the growth of the MenQuadfi market. Meningitis, an inflammation of the protective membranes surrounding the brain and spinal cord, is often caused by infections from bacteria, viruses, or fungi. If untreated, it can lead to serious complications. The rising prevalence of meningitis can be attributed to factors such as higher global travel, an increase in bacterial infections, and a growing number of immunocompromised individuals. MenQuadfi provides protection against Neisseria meningitidis, the bacteria responsible for invasive meningococcal meningitis, a life-threatening infection of the brain and spinal cord. For example, in April 2024, the Centers for Disease Control and Prevention reported 143 cases of meningococcal disease in the United States, an increase from 81 cases during the same period the previous year. Therefore, the increasing prevalence of meningitis is driving the growth of the MenQuadfi market.

The growing global travel is another key factor expected to boost the MenQuadfi market. Increased economic growth, better accessibility to affordable transportation, and a rising desire for cultural exchange and tourism are contributing to the rise in global travel. The MenQuadfi vaccine is often required for international travel to countries with a high risk of meningitis, especially in regions such as sub-Saharan Africa, to prevent the spread of the disease. According to the International Trade Administration, total international visitation increased by 31% from 2022, with overseas arrivals to the United States growing by 31%, visitors from Canada rising by nearly 43%, and those from Mexico increasing by about 17%. As a result, the rise in global travel is expected to drive the demand for the MenQuadfi vaccine.

The expansion of healthcare infrastructure is also expected to contribute to the growth of the MenQuadfi market. Healthcare infrastructure, which includes hospitals, clinics, laboratories, and other essential services, is growing due to population demands, advancements in medical technology, rising health awareness, and investments from both the government and private sector. As healthcare infrastructure improves, it enhances the distribution and accessibility of vaccines such as MenQuadfi, ensuring that more people in different regions can receive protection against meningococcal disease. The expansion of healthcare facilities also supports effective vaccination campaigns, public awareness initiatives, and better storage capacities, all of which increase overall demand for the vaccine. For example, in May 2023, the American Hospital Association reported that the United States had 6,129 hospitals, reflecting a slight increase from the previous year. Thus, the growing healthcare infrastructure is driving the growth of the MenQuadfi market.

The key company operating in the menquadfi market is Sanofi S.A.

North America was the largest region in the menquadfi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in menquadfi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the menquadfi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

MenQuadfi is a quadrivalent meningococcal conjugate vaccine designed to protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. It uses tetanus toxoid as a protein carrier to enhance the immune response and is approved for use in individuals aged two years and older. MenQuadfi provides broad, long-lasting protection and can be used for both primary immunization and booster doses. Its unique formulation ensures consistent immunogenicity across all four serogroups and age groups, addressing a critical need in the global prevention of meningococcal disease.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of vaccines for MenQuadfi are conjugate vaccines and combination vaccines. A conjugate vaccine combines a weak antigen with a strong antigen to boost the body's immune response. MenQuadfi is used for meningococcal disease prevention, outbreak control, travel vaccination, and routine immunization. It is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and public health departments (government). MenQuadfi is utilized by infants and young children, adolescents, adults, and older adults in settings such as hospitals, specialty clinics, vaccination centers, academic and research institutions, and homecare environments.

The menquadfi market consists of sales of meningococcal vaccines, pneumococcal vaccines, influenza vaccines, and hepatitis vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.